RCRobert Alarcón Cedeño

Robert Alarcón Cedeño

*This is an algorithmically generated author record based on publicly available information.

Robert Alarcón Cedeño has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tratamiento farmacológico de pacientes con insuficiencia cardíaca crónica. Subanálisis de un registro ecuatoriano

    by Luis Moreno-Rondón, María Elizabeth Ortega-Armas, Diego Pulla, Robert Alarcón Cedeño, Juan Díaz Heredia, Diego Villavicencio, Oscar Luces-Tejada, Mario Gómez, Alex Castro-Mejía

    Introduction. Introduction. In Ecuador, there is limited data on the treatment of patients with heart failure (HF). Objective. This study aimed to determine the rate of use of prognosis-modifying drugs and their association with prognosis. Materials and methods. A retrospective observational study was conducted on patients with chronic HF included in the “Los Ceibos” registry between January 2017 and December 2022. Patients were followed for a median of 2.28 years (interquartile range [IQR]: 1.25-3.49). Results. A total of 711 patients diagnosed with HF were included. Among them, 82.7% (n=588) received angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or angiotensin receptor–neprilysin inhibitors (ARNIs); 82.3% (n=585) received beta-blockers (BBs); and 51.3% (n=365) were treated with mineralocorticoid receptor antagonists (MRAs). Among patients with HFrEF, those receiving triple therapy (ACEI/ARB/ARNI + BB + MRA) had lower all-cause mortality compared to other groups (38.8%, log-rank p=0.014). In patients with Heart Failure with preserved Ejection Fraction (HFpEF), no mortality differences were observed according to the number of medications used (log-rank p=0.720). MRA use was not associated with a prognostic benefit in HFpEF (p>0.05). Patients receiving triple therapy with ARNI + BB + MRA had better survival during follow-up compared to any other drug combination (log-rank p=0.027). Conclusions. A high rate of ACEI/ARB/ARNI and BB use was observed. The use of triple therapy, particularly the combination of ARNI + BB + MRA, was associated with improved prognosis in patients with HFrEF over a four-year follow-up period. No prognostic benefit of MRA use was observed in patients with HFpEF.

  • Open Access

    Survival in Patients with Brugada Phenocopy. Case Series

    by Luis Mariano De la Torre Fonseca, Robert Alarcón Cedeño, Lileska Andreína Hernandez Bello, Juan Díaz-Heredia, Diego Milton Pulla Quezada, Rubén Andrés Guamán Castro, Pablo Juan-Salvadores

    Introduction Brugada phenocopy (BP) refers to a situation in which the characteristic electrocardiographic patterns of Brugada syndrome (BS) are temporarily manifested, which are indistinguishable from the type 1 (coved) and 2 (saddleback) patterns of BS. Several additional criteria must be considered for an accurate diagnosis. These include the presence of an identifiable underlying cause, regression of the pattern once this cause is corrected, low pretest probability of BS, a negative result of a pharmacological induction test, and a negative genetic [...] Introduction Brugada phenocopy (BP) refers to a situation in which the characteristic electrocardiographic patterns of Brugada syndrome (BS) are temporarily manifested, which are indistinguishable from the type 1 (coved) and 2 (saddleback) patterns of BS. Several additional criteria must be considered for an accurate diagnosis. These include the presence of an identifiable underlying cause, regression of the pattern once this cause is corrected, low pretest probability of BS, a negative result of a pharmacological induction test, and a negative genetic

  • Open Access

    Sobrevida em Pacientes com Fenocópia de Brugada. Série de Casos

    by Luis Mariano De la Torre Fonseca, Robert Alarcón Cedeño, Lileska Andreína Hernandez Bello, Juan Díaz-Heredia, Diego Milton Pulla Quezada, Rubén Andrés Guamán Castro, Pablo Juan-Salvadores

    Introdução A fenocópia de Brugada (FB) se refere a uma situação na qual os padrões eletrocardiográficos característicos da síndrome de Brugada (SB) são temporariamente manifestados, os quais são indistinguíveis dos padrões tipo 1 (coberto) e 2 (sela) da SB. Vários critérios adicionais devem ser considerados para um diagnóstico preciso. Estes incluem a presença de uma causa subjacente identificável, regressão do padrão uma vez que esta causa é corrigida, baixa probabilidade pré-teste de SB, um resultado negativo de um teste de [...] Introdução A fenocópia de Brugada (FB) se refere a uma situação na qual os padrões eletrocardiográficos característicos da síndrome de Brugada (SB) são temporariamente manifestados, os quais são indistinguíveis dos padrões tipo 1 (coberto) e 2 (sela) da SB. Vários critérios adicionais devem ser considerados para um diagnóstico preciso. Estes incluem a presença de uma causa subjacente identificável, regressão do padrão uma vez que esta causa é corrigida, baixa probabilidade pré-teste de SB, um resultado negativo de um teste de


  • Percutaneous gastric embolization for obesity: A prospective mid-term outcomes study

    by Carlos Ivan Soledispa Suárez, Robert Alarcón Cedeño, Luis Mariano de la Torre Fonseca, Stephanie Susana Alberca Bonilla, Fabiola Loor Cedeño, Mayra Elizabeth Briones Fajardo, Pablo Juan-Salvadores

  • Embolización gástrica percutánea en pacientes con obesidad: un estudio prospectivo de resultados a medio plazo

    by Carlos Ivan Soledispa Suárez, Robert Alarcón Cedeño, Luis Mariano de la Torre Fonseca, Stephanie Susana Alberca Bonilla, Fabiola Loor Cedeño, Mayra Elizabeth Briones Fajardo, Pablo Juan-Salvadores


  • Open Access

    Predictores de complicaciones cardiovasculares en pacientes geriátricos con síndrome coronario agudo

    by Luis M De la Torre Fonseca, Luis M Vertía Salfrán, Robert Alarcón Cedeño, Jeanette Fernández de Castro Sarmiento, Wendy G Castañeta Palmer

    Introduction: acute coronary syndromes (ACS) complications have an adverse impact on patientmorbidity and mortality, and are related to certain risk factors. Aim: to determine the predictors of cardiovascular complications in geriatric patients with ACS. Materials and methods: cohort study, retrospective and cross-sectional study in 827 patients over 60 years of age, admitted to the Hospital Docente Clínico Quirúrgico Comandante Manuel Fajardo, between 2016 - 2021. Results: The average age was 76.59 years and 58.89% of the patients were female. Hypertensive patients (88.1%) and a history of ischemic heart disease (62.3%) prevailed. There were 199 patients (24.06%) with cardiovascular complications, associated with a history of ischemic heart disease (p=0.002, OR>1); while hemodynamic complications (73.87%) were associated with female sex, history of HTN and unstable angina (p1). The risk of cardiovascular complications was increased in diabetics (p<0.05) and the risk of hemodynamic complications was also increased in women, patients with a history of diabetes mellitus and HTN (p<0.05). Conclusions: in ACS, diabetes mellitus is a predictor of cardiovascular complications; and female sex, diabetes mellitus and hypertension are predictors of hemodynamic complications.

  • Open Access

    Percutaneous Gastric Embolisation in Obese Patients: A Prospective Study of Mid-Term Outcomes

    by Carlos Ivan Soledispa Suárez, Robert Alarcón Cedeño, Luis Mariano de la Torre Fonseca, Stephanie Susana Alberca Bonilla, Fabiola Loor Cedeño, Mayra Elizabeth Briones Fajardo, Pablo Juan Salvadores

    Introduction Obesity represents one of the most pressing public health challenges that needs to be solved globally, with serious health implications. Percutaneous gastric embolisation has emerged as a promising technique in the management of obesity. Objective This study aims to evaluate the relationship between endovascular procedure and weight loss in obese patients. In addition, to determine the complications related to percutaneous gastric embolisation in these patients. Design: Prospective longitudinal cohort study during the period from 1 January to 31 December 2022 and received treatment with percutaneous gastric embolisation Setting: This study includes patients admitted to the Haemodynamics Service of the Cardiovascular Health Institute during the year 2022. Participants: This study includes 15 patients diagnosed with grade III obesity who met the following criteria: patients ≥ 18 years with a diagnosis of obesity as determined by a body mass index greater than 30 kg/m2 and less than 40 kg/m 2, admitted between January to December 2022, and patients with a diagnosis of obesity with BMI > 40 kg/m2 with contraindication or refusal of bariatric. Main Outcome(s) and Measure(s): This is one of the largest studies in percutaneous gastric embolisation an obese population, while assessing the sustainability of weight loss outcomes. The main findings of the study can be summarised as follows: a) The procedure is safe without major complications, ulcers or gastric ischaemia, b) These technique achieves significant weight loss that is maintained over time. Results 86.7% were successful. Treated patients experienced significant weight loss when comparing baseline weight (101.2 ± 23.0 SE = 5.9) with weight at 6 months after the interventional procedure (91.5 ± 19.8, SE = 5.1) t(14) = 5.3, p < 0.001, d = 0.45. Especially males (106.7 ± 18.4, p = 0.01). No major vascular complications, gastric ulcer or ischaemia, or abdominal symptoms were documented in any of the patients included in the study. Only 6 patients (40%) presented with epigastralgia, 9 (60%) with nausea and 3 (20%) with vomiting. Conclusions Percutaneous gastric embolisation is an effective and safe procedure to reduce body mass index with a high success rate, well tolerated by obese patients, without major complications, whose results are maintained over time.

  • Open Access

    Temporal Trends and Contemporary Outcomes After Transcatheter Aortic Valve Replacement With Evolut PRO/PRO+ Self-Expanding Valves: Insights From the NEOPRO/NEOPRO-2 Registries

    by Andrea Scotti, Sara Baggio, Matteo Pagnesi, Marco Barbanti, Marianna Adamo, Amnon Eitan, Rodrigo Estévez-Loureiro, Verena Veulemans, Stefan Toggweiler, Darren Mylotte, et al.

    Background: In recent years, transcatheter aortic valve replacement (TAVR) techniques and technology have continuously improved. Data regarding the impact of these advancements on outcomes in large real-world settings are still limited. The aim of this study was to investigate temporal trends and assess contemporary outcomes after TAVR with Evolut PRO/PRO+ supra-annular self-expanding valves. Methods: This study included patients enrolled in the multicenter NEOPRO (A Multicenter Comparison of Acurate NEO Versus Evolut PRO Transcatheter Heart Valves) and NEOPRO-2 (A Multicenter Comparison of ACURATE NEO2 Versus Evolut PRO/PRO+ Transcatheter Heart Valves 2) registries who underwent transfemoral TAVR with Evolut PRO/PRO+. Procedural dates (August 2017 through November 2021) were stratified in quartiles (Q) and used to investigate temporal trends in TAVR outcomes. Predischarge, 30-day Valve Academic Research Consortium-3 defined, and 1-year outcomes were evaluated. Results: In total, 1616 patients from 28 centers were included. Over time, patients had lower Society of Thoracic Surgeon-Predicted Risk of Mortality score (Q1–4, 4.1% [2.8–6.3%], 3.7% [2.6–5.3%], 3.3% [2.4–4.9%], 2.9% [2.2–4.3%]; P P =0.038). Overall Valve Academic Research Consortium-3 technical success was 94.1%, with 30-day and 1-year all-cause mortality of 2.4% and 10%, respectively. Throughout the study period, procedures were associated with higher rates of 30-day device success (Q1–4, 81.2%, 82.2%, 82.0%, 88.0%; Cochran-Armitage P =0.023) and early safety (Q1–4, 66.8%, 67.5%, 74.0%, 77.6%; Cochran-Armitage P P =0.023) and residual mild or greater paravalvular leaks (Q1–4, 50.4%, 42.1%, 36.5%, 35.8%; Cochran-Armitage P <0.001). Conclusions: TAVR with Evolut PRO/PRO+ self-expanding valve is safe and effective. Despite the treatment of heavier calcified anatomies, procedural outcomes are improving over time with less need for pacemaker implantation and less significant paravalvular leaks.


  • Válvula Tendyne facilitada por laceración anterior mitral anterógrada

    by Robert Alarcón, Manuel Barreiro-Pérez, Rodrigo Estévez-Loureiro


  • Percutaneous Retrieval of Dislodged Device With Double Biopsy Forceps During Double-Device LAAO

    by Manuel Barreiro-Perez, Rodrigo Estevez-Loureiro, Robert Alarcon, Berenice Caneiro-Queija, Jose Antonio Baz, Andres Iñiguez-Romo